GSK Vows To Eradicate Lymphatic Filariasis By 2020
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - GlaxoSmithKline is taking steps to eradicate lymphatic filariasis, a crippling tropical disease that is estimated to cost the Indian economy $840 million each year. GSK plans to invest nearly $340,000 in its Nashik, India facility and double its current global capacity for the production of albendazole